\BOOKMARK [1][-]{Doc-Start}{Biographical Sketch}{}% 1
\BOOKMARK [1][-]{chapter*.1}{Dedication}{}% 2
\BOOKMARK [1][-]{chapter*.1}{Acknowledgements}{}% 3
\BOOKMARK [1][-]{chapter*.2}{Table of Contents}{}% 4
\BOOKMARK [1][-]{chapter*.2}{List of Tables}{}% 5
\BOOKMARK [1][-]{chapter*.2}{List of Figures}{}% 6
\BOOKMARK [0][-]{chapter.1}{Introduction}{}% 7
\BOOKMARK [0][-]{chapter.2}{Predicting the selectivity of small molecule kinase inhibitors}{}% 8
\BOOKMARK [1][-]{section.2.1}{Introduction}{chapter.2}% 9
\BOOKMARK [2][-]{subsection.2.1.1}{Free energy methods can aid structure-based drug design}{section.2.1}% 10
\BOOKMARK [2][-]{subsection.2.1.2}{Selectivity is an important consideration in drug design}{section.2.1}% 11
\BOOKMARK [2][-]{subsection.2.1.3}{Use of physical modeling to predict selectivity is relatively unexplored}{section.2.1}% 12
\BOOKMARK [2][-]{subsection.2.1.4}{Kinases are an interesting and particularly challenging model system for selectivity predictions}{section.2.1}% 13
\BOOKMARK [2][-]{subsection.2.1.5}{Assessing the ability of alchemical free energy methods to predict selectivity}{section.2.1}% 14
\BOOKMARK [1][-]{section.2.2}{Methods}{chapter.2}% 15
\BOOKMARK [2][-]{subsection.2.2.1}{Numerical model of selectivity}{section.2.2}% 16
\BOOKMARK [2][-]{subsection.2.2.2}{Structure Preparation}{section.2.2}% 17
\BOOKMARK [2][-]{subsection.2.2.3}{Ligand Pose Generation}{section.2.2}% 18
\BOOKMARK [2][-]{subsection.2.2.4}{Free Energy Calculations}{section.2.2}% 19
\BOOKMARK [2][-]{subsection.2.2.5}{Charge Change Free Energy Calculations}{section.2.2}% 20
\BOOKMARK [2][-]{subsection.2.2.6}{Statistical Analysis of FEP+ calculations}{section.2.2}% 21
\BOOKMARK [2][-]{subsection.2.2.7}{Quantification of the correlation coefficient }{section.2.2}% 22
\BOOKMARK [1][-]{section.2.3}{Results}{chapter.2}% 23
\BOOKMARK [2][-]{subsection.2.3.1}{Free energy methods can be used to predict the selectivity of a compound}{section.2.3}% 24
\BOOKMARK [2][-]{subsection.2.3.2}{Correlation of errors can make selectivity predictions more accurate and speed up ligand optimization}{section.2.3}% 25
\BOOKMARK [2][-]{subsection.2.3.3}{The CDK2 and CDK9 experimental dataset demonstrates the difficulty in achieving selectivity for closely related kinases}{section.2.3}% 26
\BOOKMARK [2][-]{subsection.2.3.4}{The CDK2 and ERK2 dataset achieves higher levels of selectivity for more distantly related kinases}{section.2.3}% 27
\BOOKMARK [2][-]{subsection.2.3.5}{FEP+ calculations show accurate potency predictions for ERK2/CDK2 and larger errors for CDK2/CDK9}{section.2.3}% 28
\BOOKMARK [2][-]{subsection.2.3.6}{Free energy calculation errors are correlated, accelerating selectivity optimization}{section.2.3}% 29
\BOOKMARK [1][-]{section.2.4}{Discussion and Conclusions}{chapter.2}% 30
\BOOKMARK [0][-]{chapter.3}{Understanding the functional impact of mTOR clinical kinase mutations using physical modeling}{}% 31
\BOOKMARK [1][-]{section.3.1}{Introduction}{chapter.3}% 32
\BOOKMARK [2][-]{subsection.3.1.1}{mTOR forms the catalytic core of protein complexes that control a number of cellular processes}{section.3.1}% 33
\BOOKMARK [2][-]{subsection.3.1.2}{mTOR is the targeted by inhibitors with two distinct mechanisms of action}{section.3.1}% 34
\BOOKMARK [2][-]{subsection.3.1.3}{mTOR signaling is dysregulated in cancer by hyperactivating missense mutations}{section.3.1}% 35
\BOOKMARK [2][-]{subsection.3.1.4}{Using physical modeling to understand the functional impact of mTOR mutations}{section.3.1}% 36
\BOOKMARK [1][-]{section.3.2}{Methods}{chapter.3}% 37
\BOOKMARK [2][-]{subsection.3.2.1}{Molecular dynamics simulations}{section.3.2}% 38
\BOOKMARK [2][-]{subsection.3.2.2}{Contact Map Analysis}{section.3.2}% 39
\BOOKMARK [2][-]{subsection.3.2.3}{Mean Contact formation over time}{section.3.2}% 40
\BOOKMARK [2][-]{subsection.3.2.4}{Alchemical free energy calculations}{section.3.2}% 41
\BOOKMARK [1][-]{section.3.3}{Results}{chapter.3}% 42
\BOOKMARK [2][-]{subsection.3.3.1}{Missense mutations perturb the structure of mTOR kinase domain}{section.3.3}% 43
\BOOKMARK [2][-]{subsection.3.3.2}{Missense mutations do not appear to shift the formation of an active kinase domain}{section.3.3}% 44
\BOOKMARK [2][-]{subsection.3.3.3}{Missense mutations do not disrupt the formation of inhibitory salt bridges between the kinase and FAT domains}{section.3.3}% 45
\BOOKMARK [1][-]{section.3.4}{Conclusions}{chapter.3}% 46
\BOOKMARK [0][-]{chapter.4}{Predicting the impact of clinically-observed Abl inhibitors using physical modeling and biophysical experiments}{}% 47
\BOOKMARK [1][-]{section.4.1}{Introduction}{chapter.4}% 48
\BOOKMARK [2][-]{subsection.4.1.1}{The long tail of rare kinase mutations frustrates prediction of drug resistance}{section.4.1}% 49
\BOOKMARK [2][-]{subsection.4.1.2}{Alchemical free-energy methods can predict inhibitor binding affinities}{section.4.1}% 50
\BOOKMARK [2][-]{subsection.4.1.3}{Alchemical approaches can predict the impact of protein mutations on free energy}{section.4.1}% 51
\BOOKMARK [2][-]{subsection.4.1.4}{Assessing the potential for physical modeling to predict resistance to FDA-approved TKIs}{section.4.1}% 52
\BOOKMARK [2][-]{subsection.4.1.5}{A benchmark of pIC50s for predicting mutational resistance}{section.4.1}% 53
\BOOKMARK [2][-]{subsection.4.1.6}{Summary of experimental data that is available and what needs to be done to make better information available}{section.4.1}% 54
\BOOKMARK [2][-]{subsection.4.1.7}{Open-source YANK/Amber forcefield stuff}{section.4.1}% 55
